Monobasic Sodium Phosphate And Dibasic Sodium Phosphate

Constipation, Gastroenteritis, Electrolyte imbalance + 27 more

Treatment

6 FDA approvals

20 Active Studies for Monobasic Sodium Phosphate And Dibasic Sodium Phosphate

What is Monobasic Sodium Phosphate And Dibasic Sodium Phosphate

Sodium phosphate, monobasic

The Generic name of this drug

Treatment Summary

Sodium phosphate is a laxative that helps stimulate bowel movements. It works by increasing fluid in the small intestine, typically resulting in a bowel movement within 30 minutes to 6 hours.

K Phos Neutral

is the brand name

Monobasic Sodium Phosphate And Dibasic Sodium Phosphate Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

K Phos Neutral

Sodium phosphate, monobasic

1977

124

Approved as Treatment by the FDA

Sodium phosphate, monobasic, otherwise known as K Phos Neutral, is approved by the FDA for 6 uses including Hypophosphatemia and Bowel preparation therapy .

Hypophosphatemia

Bowel preparation therapy

Renal Replacement Therapy

Parenteral Nutrition, Total

Hypophosphatemia

Hypophosphatemia

Effectiveness

How Monobasic Sodium Phosphate And Dibasic Sodium Phosphate Affects Patients

Sodium phosphate helps make stool softer and move more quickly through the large intestine.

How Monobasic Sodium Phosphate And Dibasic Sodium Phosphate works in the body

Sodium phosphate is thought to work by making the intestine more watery, which helps stools become softer and pass more easily.

When to interrupt dosage

The quantity of Monobasic Sodium Phosphate And Dibasic Sodium Phosphate is contingent upon the determined condition, including fluid and electrolyte maintenance therapy, Fluid replacement therapy and Irrigation. The extent of dosage contrasts as per the delivery technique (e.g. Liquid or Tablet, coated) delineated in the accompanying table.

Condition

Dosage

Administration

Bowel preparation therapy

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

postoperative fluid imbalance

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

sigmoidoscopy

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

proctoscopy

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

Management Audit

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

Acid-Base Imbalance

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

Gastroenteritis

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

Parenteral Nutrition, Total

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

Red Blood Cell Count measurement

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

Colonoscopy

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

Electrolyte replacement therapy

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

intraocular surgery

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

postoperative electrolyte imbalance

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

Hypophosphatemia

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

Electrolyte imbalance

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

Acidosis

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

Constipation

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

Hypophosphatemia

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

Irrigation

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

Electrolyte replacement

, 700.0 mg, 2.76 mg/mL, 14.0 mg/mL, 15.5 mg/mL, 22.2 mg/mL, 27.6 mg/mL, 7.8 mg/mL, 40.8 mg, 1.61 %, 0.408 mg/mg, 0.16 mg/mL, 1102.0 mg, 500.0 mg, 350.0 mg, 0.14 %, 276.0 mg/mL, 130.0 mg, 222.0 mg, 10.9 mg/mL, 2.22 mg/mL, 8.79 mg/mL, 7.28 mg/mL, 0.25 mg/mL, 0.2 mg/mL, 1105.0 mg, 0.145 mL/mL, 0.93 mg/mL, 31.1 mg/mL, 2.07 mg/mL, 0.222 %, 2510.0 mg, 276.0 mg, 2.8 mg/mL, 0.78 mg/mL, 480.0 mg/mL, 8790.0 mg/mL, 2400.0 mg/mL, 160.0 mg/mL, 125.0 mg, 129.1 mg/mL, 2.2 mg/mL, 0.517 mg/mL, 1.05 mg/mL, 1.4 mg/mL, 1.81 mg/mL

, Oral, Tablet, coated, Tablet, coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Intravenous, Extracorporeal, Solution - Extracorporeal, Tablet, Tablet - Oral, Capsule, Capsule - Oral, Liquid, Intravesical, Dental, Liquid - Intravesical, Paste, Liquid - Oral, Paste - Dental, Tablet, effervescent - Oral, Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Oral, Irrigation, Liquid - Irrigation, Rectal, Enema, Enema - Rectal, Injection, Injection - Intrathecal, Intrathecal, Kit, Kit - Intravenous, Tablet, sugar coated, Tablet, sugar coated - Oral, Tablet, film coated, Tablet, film coated - Oral, Liquid - Intravenous

Warnings

Monobasic Sodium Phosphate And Dibasic Sodium Phosphate has four contraindications and should not be consumed when experiencing the conditions specified in the following table.

Monobasic Sodium Phosphate And Dibasic Sodium Phosphate Contraindications

Condition

Risk Level

Notes

biopsy-proven acute phosphate nephropathy

Do Not Combine

Hypernatremia

Do Not Combine

calcium

Do Not Combine

high phosphate levels

Do Not Combine

There are 20 known major drug interactions with Monobasic Sodium Phosphate And Dibasic Sodium Phosphate.

Common Monobasic Sodium Phosphate And Dibasic Sodium Phosphate Drug Interactions

Drug Name

Risk Level

Description

Alloin

Minor

The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Alloin.

Carboxymethylcellulose

Minor

The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Carboxymethylcellulose.

Castor oil

Minor

The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Castor oil.

Chlorpropamide

Minor

Sodium phosphate, monobasic may decrease the excretion rate of Chlorpropamide which could result in a higher serum level.

Deacetylbisacodyl

Minor

The risk or severity of adverse effects can be increased when Sodium phosphate, monobasic is combined with Deacetylbisacodyl.

Monobasic Sodium Phosphate And Dibasic Sodium Phosphate Toxicity & Overdose Risk

The highest toxic dose of sodium phosphate found in rats is 250mg/kg when injected and 8290mg/kg when taken orally. High levels of phosphate can cause symptoms such as muscle spasms, dehydration, low blood pressure, rapid heartbeat, high fever, and unconsciousness. Smaller patients may be at higher risk for developing phosphate toxicity.

Monobasic Sodium Phosphate And Dibasic Sodium Phosphate Novel Uses: Which Conditions Have a Clinical Trial Featuring Monobasic Sodium Phosphate And Dibasic Sodium Phosphate?

54 active studies are in progress to assess the utility of Monobasic Sodium Phosphate and Dibasic Sodium Phosphate for Electrolyte replenishment, proctoscopy and Irrigation.

Condition

Clinical Trials

Trial Phases

Electrolyte replacement

0 Actively Recruiting

Fluid replacement therapy

0 Actively Recruiting

Renal Replacement Therapy

1 Actively Recruiting

Phase 3

postoperative electrolyte imbalance

0 Actively Recruiting

proctoscopy

0 Actively Recruiting

Hypophosphatemia

1 Actively Recruiting

Phase 2

Colonoscopy

3 Actively Recruiting

Not Applicable

fluid and electrolyte maintenance therapy

0 Actively Recruiting

Electrolyte imbalance

0 Actively Recruiting

Bowel preparation therapy

1 Actively Recruiting

Phase 1, Phase 2

Electrolyte replacement therapy

0 Actively Recruiting

postoperative fluid imbalance

0 Actively Recruiting

Gastroenteritis

12 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Early Phase 1

Irrigation

0 Actively Recruiting

Red Blood Cell Count measurement

0 Actively Recruiting

Parenteral Nutrition

0 Actively Recruiting

Metabolic acidosis

0 Actively Recruiting

sigmoidoscopy

0 Actively Recruiting

Rehydration

0 Actively Recruiting

Constipation

18 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 3, Phase 1

Patient Q&A Section about monobasic sodium phosphate and dibasic sodium phosphate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between monobasic and dibasic potassium phosphate?

"Monobasic and dibasic refers to the number of potassium cations bound to the phosphate molecule. KH2PO4 is monobasic and can release a low amount of potassium, whereas K2HPO4 is dibasic and can release a high amount of potassium when used in fertilizer."

Answered by AI

What does dibasic sodium phosphate do?

"Sodium Phosphate Dibasic is a white powder that is odorless and has a sand-like texture. It is used to create starch, as well as an emulsifier in various foods. Additionally, it is involved in the production of enamels, ceramics and detergents."

Answered by AI

What is meant by monobasic sodium phosphate?

"Monosodium phosphate is a salt composed of sodium and dihydrogen phosphate. It is a common industrial chemical that exists in an anhydrous form, as well as mono- and dihydrates."

Answered by AI

Clinical Trials for Monobasic Sodium Phosphate And Dibasic Sodium Phosphate

Image of Johns Hopkins Bayview Medical Center in Baltimore, United States.

VR-Enhanced PMR for Post-Burn Symptoms

18+
All Sexes
Baltimore, MD

The goal of this clinical trial is to learn whether progressive muscle relaxation (PMR), delivered either alone or enhanced with virtual reality (VR), can help treat chronic symptom, such as pain, itch, anxiety, sleep disturbances, and fatigue, in adult burn survivors. The main questions it aims to answer are: * Does VR-enhanced PMR (VR-PMR) reduce chronic pain, anxiety, itch, sleep disturbances, and fatigue more effectively than standard PMR? * Is VR-PMR a feasible and acceptable self-administered home-based intervention for burn survivors? Researchers will compare two self-administered intervention conditions, VR-enhanced PMR and standard PMR, using a randomized to sequence crossover design to see if VR technology enhances the therapeutic effects of PMR on chronic symptom management in burn survivors. Participants will: * Complete home-based sessions of VR-enhanced PMR * Complete home-based sessions of standard PMR * Report symptoms such as pain, itch, anxiety, sleep disturbances, and fatigue throughout the study * Use VR equipment provided for the intervention period (during the VR-PMR arm)

Recruiting
Has No Placebo

Johns Hopkins Bayview Medical Center

Sheera Lerman Zohar, PhD

Image of University of Iowa Hospitals and Clinics in Iowa City, United States.

Post-Filter Hematocrit for Kidney Failure

18+
All Sexes
Iowa City, IA

Filter clotting is a major complication of continuous renal replacement therapy (CRRT), resulting in blood loss, reduced treatment efficacy, and increased cost. One modifiable factor associated with filter clotting is filtration fraction (FF), or the proportion of plasma water being removed from the blood over the course of the filter. In convention, a cutoff of FF\<20-30% has been used to prevent hemofilter clotting, but no evidence correlating FF with hemofilter clotting has been documented. Some experts have proposed that post-filter hematocrit (Hct) could be a more direct marker for determining hemofilter clotting risk, but evidence supporting clinical utility of this marker is lacking. HCTpost=HCTpre/(FF(HCTpre-1)+1) In our proposed validation study, we hope to determine whether our formula for post-filter Hct provides accurate results when compared to measured values. The information obtained from this study will potentially justify the use of utilizing the formula in future studies. The procedure of this study is collecting blood samples from the post-filter lines of patients on CRRT at different time points and different flow rates. This will be considered the "measured post-filter hematocrit" which will then be compared to the calculated formula above, using the other values obtained from daily labs (for pre-filter hematocrit) and CRRT machine settings.

Recruiting
Has No Placebo

University of Iowa Hospitals and Clinics

Image of St. John's Rehab at Sunnybrook in Toronto, Canada.

Peer Support Program for Traumatic Injury

18+
All Sexes
Toronto, Canada

Traumatic injuries from events like car crashes, falls, or fires are a leading cause of disability. Survivors often face not only physical challenges but also long-lasting pain, mental health challenges and difficulty returning to work and family life. Although medical care focuses on physical recovery, survivors frequently report that their emotional and social needs are overlooked and unmet. Peer support-guidance from people who have lived through similar injuries-can reduce distress and improve coping. However, no programs in Canada currently provide peer support to trauma survivors across their recovery journey, from hospital to rehabilitation to community living. The investigators worked with trauma survivors, caregivers, and healthcare providers to co-design a Peer Support Program (PSP) that offers support throughout these stages. This pilot study will test whether the program is feasible and acceptable, and explore its early impact on recovery. Results will guide a future larger trial to expand peer support in trauma care.

Waitlist Available
Has No Placebo

St. John's Rehab at Sunnybrook (+1 Sites)

Marina Wasilewski, PhD

Image of Stanford Digestive Health Clinic in Redwood City, United States.

MITI-001 for Irritable Bowel Syndrome

18 - 65
All Sexes
Redwood City, CA

While the pathophysiology of diarrhea-predominant irritable bowel syndrome (IBS-D) is complex and heterogeneous, dysbiosis of the gut microbiome is frequently observed, suggesting that a substantial subset of patients with irritable bowel syndrome (IBS) have symptoms that are initiated and/or perpetuated by a microbiome dysfunction. Successful randomized controlled trials (RCT) for IBS-D (Ford 2018; Black 2022) leveraging microbiome-targeted therapies (antibiotics or low microbiome fermentation diets) suggest the gut microbiome is at least partially involved in IBS symptoms. Furthermore, fecal microbiota transplantation (FMT) for patients with IBS-D has demonstrated promising results (El-Salhy 2020), supporting the possibility that altering the microbiome composition could ameliorate IBS-D symptoms. MITI-001 is a transplantable gut bacterial community composed of 157 live bacterial strains, encompassing 79 genera of commensal bacteria, that have been isolated from healthy donor stool, purified, and banked. The hypothesis of the proposed research is that MITI-001 can target the pathophysiologic lesion in a subset of IBS-D patients, restore the altered microbial metabolic process, and thus alleviate IBS-D symptoms.

Phase < 1
Waitlist Available

Stanford Digestive Health Clinic (+1 Sites)

Sean P Spencer, MD, PhD

Have you considered Monobasic Sodium Phosphate And Dibasic Sodium Phosphate clinical trials?

We made a collection of clinical trials featuring Monobasic Sodium Phosphate And Dibasic Sodium Phosphate, we think they might fit your search criteria.
Go to Trials

Have you considered Monobasic Sodium Phosphate And Dibasic Sodium Phosphate clinical trials?

We made a collection of clinical trials featuring Monobasic Sodium Phosphate And Dibasic Sodium Phosphate, we think they might fit your search criteria.
Go to Trials
Image of Mercy Hospital in Pittsburgh, United States.

Fat Grafting for Burns

18+
All Sexes
Pittsburgh, PA

The goal of this study is to explore if an adipose-based therapeutic strategy can treat full-thickness soft-tissue trauma wounds in injured individuals, especially those with severe burns or soft-tissue loss. The main question it aims to answer are: \- Can immediate autologous adipose and autologous layered composite grafting be effective for acute functional soft-tissue reconstruction? Researchers will compare the single-stage autologous layered composite grafting method to traditional methods to see if it improves healing outcomes, minimizes scarring, and reduces infection risk. Participants will: * Receive immediate fat grafting into the wound. * Undergo simultaneous split-thickness skin grafting for full soft-tissue reconstruction.

Waitlist Available
Has No Placebo

Mercy Hospital (+1 Sites)

Francesco Egro

Image of Mercy Hospital in Pittsburgh, United States.

Autologous Fat-Based Therapy for Scar Tissue

18+
All Sexes
Pittsburgh, PA

The goal of this study is to explore if an adipose-based therapeutic strategy can treat contracted scars secondary to soft-tissue burn wounds in injured individuals, especially those with severe burns or soft-tissue loss. The main question it aims to answer are: \- Can autologous layered composite grafting demonstrate non-inferiority compared to full-thickness skin grafting for delayed reconstruction of post-burn or trauma scar contracture? Researchers will compare the single-stage autologous layered composite grafting method to traditional methods to see if it improves healing outcomes, minimizes scarring, and reduces infection risk. Participants will: * Receive fat grafting at time of scar revision. * Undergo simultaneous split-thickness skin grafting for full soft-tissue reconstruction.

Waitlist Available
Has No Placebo

Mercy Hospital (+1 Sites)

Francesco Egro

Image of Hamilton Health Sciences in Hamilton, Canada.

Kiwifruit Extract for Constipation in Children

4 - 17
All Sexes
Hamilton, Canada

The goal of this pilot feasibility randomized controlled trial is to determine whether Actazin (kiwifruit extract) is a feasible and effective alternative to polyethylene glycol 3350 (PEG 3350) for maintenance therapy in children with functional constipation (FC). This study will include children aged 4 to 17 years who meet the Rome IV criteria for functional constipation. The main questions it aims to answer are: 1. Is it feasible to conduct a definitive, multi-centre trial comparing Actazin to PEG 3350 in children with FC? 2. What are the within-group differences in clinical outcomes such as stool frequency, abdominal pain, and laxative use over a 4-week period? Researchers will compare chewable Actazin tablets with placebo PEG 3350 powder to PEG 3350 powder with placebo Actazin tablets to see if Actazin is a viable non-pharmacologic natural health product alternative for treating FC. Participants will: Undergo an initial bowel cleanout using PEG 3350 and bisacodyl. Following, they will be randomized to one of two groups: 1. Actazin chewable tablets (titrate to effect: 600-2400 mg/day) + placebo PEG 3350 2. PEG 3350 (dose based on age and titratable to effect) + placebo Actazin chewable tablets Participants will take the assigned intervention daily for 4 weeks and complete a daily bowel diary recording stool frequency, consistency (Bristol Stool Scale), abdominal pain, and laxative use. They will have weekly follow-ups via phone or electronic survey to assess adherence, medication use, and adverse events. Additionally, a bi-weekly follow-up will be conducted for an additional 8 weeks to track longer-term outcomes. Outcomes: Primary feasibility outcomes include consent rate, adherence to allocated intervention, and 4-week follow-up completion rate. Secondary clinical outcomes include resolution of FC (Rome IV criteria), weekly stool frequency, abdominal pain episodes, use of rescue laxatives, and treatment palatability. This study is being conducted at McMaster Children's Hospital and is funded by the Hamilton Academic Health Sciences Organization (HAHSO). Data collection will be managed using the Lumedi™ platform, and safety will be overseen by a Data Safety Monitoring Board (DSMB).

Phase 2 & 3
Waitlist Available

Hamilton Health Sciences

Elyanne Ratcliffe, MD

Have you considered Monobasic Sodium Phosphate And Dibasic Sodium Phosphate clinical trials?

We made a collection of clinical trials featuring Monobasic Sodium Phosphate And Dibasic Sodium Phosphate, we think they might fit your search criteria.
Go to Trials